Track ADMA Biologics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ADMA Biologics, Inc. ADMA · Stock Open ADMA Biologics, Inc. in new tab

13.68 USD
P/E
17.77
EPS
0.77
P/B
6.95
ROE
41.95
Beta
0.66
Target Price
18.00 USD
ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

🧾 Earnings Recap – Q3 2026

ADMA shares rose 26.0% after earnings, as investors responded to 31% year-over-year ASCENIV growth, 71% corporate gross margin and substantial earnings growth. The quarter also showed continued pressure on BIVIGAM revenue, while management pointed to early signs of stabilization in end-user utilization.

  • ASCENIV revenue was $124.7 million, up 31% year over year and 21% sequentially; management cited broader physician adoption, new patient starts and higher end-user utilization.
  • Total revenue increased 13% sequentially to $141.1 million, and corporate gross margin was 71%.
  • BIVIGAM revenue fell to $15.4 million from $19.4 million in the second quarter amid pricing and competitive pressure; management said underlying utilization showed signs of stabilization entering the fourth quarter.
  • ADMA repurchased 16.5 million shares through September 30, about 6.3% of shares outstanding at year-end 2025, and remained on track for its target of at least $200 million in 2026 repurchases.
  • Management said ASCENIV growth in secondary immunodeficiency patients has been moderate so far, despite viewing that population as a potential additional growth opportunity.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E17.77
EPS0.77
Book Value1.97
Price to Book6.95
Debt/Equity46.25
% Insiders1.969%
Growth
Revenue Growth0.05%
Earnings Growth0.47%
Estimates
Forward P/E15.72
Forward EPS0.87
Target Mean Price18.00

DCF valuation

Model fair value for ADMA Biologics, Inc. (ADMA)
Result
Sign in to run the valuation for ADMA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Buy · mean target 18.00 USD (low 13.00, high 22.00) · as of 14 Nov 2026
Low 13.00
Mean 18.00
High 22.00
Price 13.68
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ADMA Biologics, Inc. Logo ADMA Biologics, Inc. Analysis (ADMA)

United States Health Care Official Website Stock

Is ADMA Biologics, Inc. a good investment? ADMA Biologics, Inc. (ADMA) is currently trading at 13.68 USD. Market analysts have a consensus price target of 18.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 17.77. This valuation is generally in line with the broader market.

Earnings Schedule: ADMA Biologics, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 0.87.

Investor FAQ

Does ADMA Biologics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ADMA Biologics, Inc.?

ADMA Biologics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 0.77.

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Exchange Ticker
NGM (Sweden) ADMA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion